Acrux Locks in $5.4M Lenzetto Licensing Deal to Bring HRT Spray to Australia
Acrux secures AUD $5.4 million Lenzetto® licensing deal for the Australian market
Acrux Limited (ASX: ACR) has licensed Lenzetto® for the Australian market under an agreement with Gedeon Richter Plc, with total milestone payments of up to AUD $5.4 million. The deal, first announced on 28 May 2026, adds a domestic revenue stream to Acrux’s established international licensing model.
When big ASX news breaks, our subscribers know first
How the $5.4 million milestone structure works
A supplementary update released on 29 May 2026 provided the structural detail behind the headline figure, clarifying that the $5.4 million is payable across three distinct milestones rather than as a lump sum.
The three tranches are structured as follows:
- Upfront signing milestone — becomes due 14 days following execution of the amendment to the agreement.
- Regulatory milestone — receivable upon marketing authorisation from the Therapeutic Goods Authority (TGA) in Australia; Gedeon Richter Plc is responsible for TGA registration.
- Commercial milestone — receivable at the earlier of: (a) achievement of a cumulative sales target, or (b) the second anniversary following product launch.
The staggered structure means Acrux receives an immediate cash inflow at signing, with subsequent tranches contingent on regulatory and commercial progress driven by the partner rather than by Acrux itself.
| Milestone | Trigger | Responsible Party |
|---|---|---|
| Upfront signing milestone | 14 days following execution of the amendment | Automatic on execution |
| Regulatory milestone | Marketing authorisation granted by the TGA | Gedeon Richter Plc |
| Commercial milestone | Cumulative sales target achieved, or second anniversary of product launch (whichever is earlier) | Gedeon Richter Plc |
What is Lenzetto® and why does this deal matter for investors
Lenzetto® is an estradiol transdermal spray used in hormone replacement therapy (HRT), a treatment that supplements the body’s oestrogen levels in women experiencing menopausal symptoms. The product is already established internationally, and Gedeon Richter Plc is a globally recognised pharmaceutical company managing its registration and commercialisation in Australia.
For Acrux, this deal is consistent with its core business model. The company specialises in developing and commercialising topically applied pharmaceutical products, then licensing those products through partners. Drawing on 25 years of experience, Acrux has successfully brought a number of products to market worldwide through this approach, with particular emphasis on the United States.
The Australian deal extends that model into the domestic market while keeping Acrux’s cost exposure limited. Gedeon Richter Plc bears responsibility for TGA registration and commercialisation, meaning Acrux receives milestone income without carrying the associated regulatory or launch costs.
The next major ASX story will hit our subscribers first
What comes next for Acrux
The immediate next step is execution of the amendment, which triggers the 14-day window for the first payment. Following that, the focus shifts to Gedeon Richter Plc progressing TGA registration to unlock the regulatory milestone.
Key steps on the path forward include:
- Amendment execution, triggering the upfront signing milestone within 14 days
- TGA registration process, managed by Gedeon Richter Plc
- Commercial launch, with the final milestone receivable upon hitting the cumulative sales target or the second anniversary of launch
As Acrux continues building its licensing revenue base, the Lenzetto® agreement reflects its ongoing strategy of generating returns from its topical pharmaceutical expertise through established global partners, without bearing the full burden of commercialisation.
Don’t Miss the Next Healthcare Licensing Deal
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ subscribers already getting the edge on market-moving announcements. Click the “Free Alerts” button at Big News Blast to start receiving alerts the moment news breaks.